A single-ascending dose study to investigate the pharmacokinetic and pharmacodynamic profile of subcutaneously injected exendin-9 in Patients with Post-Bariatric Hypoglycemia (PBH)

Trial Profile

A single-ascending dose study to investigate the pharmacokinetic and pharmacodynamic profile of subcutaneously injected exendin-9 in Patients with Post-Bariatric Hypoglycemia (PBH)

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2016

At a glance

  • Drugs Exendin 9 (Primary)
  • Indications Hypoglycaemia
  • Focus Pharmacokinetics
  • Sponsors Eiger BioPharmaceuticals
  • Most Recent Events

    • 13 Jun 2016 According to an Eiger BioPharmaceuticals media release, results from this study were presented at the American Diabetes Association 2016 annual meeting.
    • 13 Jun 2016 Results published in the Media Release
    • 02 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top